Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
09 mai 2023 08h00 HE
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
25 avr. 2023 08h00 HE
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023
24 avr. 2023 08h00 HE
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference
18 avr. 2023 08h00 HE
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
28 mars 2023 08h00 HE
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
06 mars 2023 08h00 HE
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon Therapeutics to Participate on a Panel at Cowen’s 43rd Annual Health Care Conference
27 févr. 2023 08h00 HE
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon Therapeutics Announces Pricing of Initial Public Offering
14 nov. 2022 22h16 HE
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368
22 juin 2022 08h00 HE
|
Acrivon Therapeutics
--Pioneering trial will be using a first-of-its-kind OncoSignature® companion diagnostic to identify and treat patients that are predicted most likely to benefit from treatment— ...
Acrivon Therapeutics Announces the Appointments of Rasmus Holm-Jorgensen as Chief Financial Officer and Other Senior Executives
20 avr. 2022 08h00 HE
|
Acrivon Therapeutics
WATERTOWN, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based...